Compounding Drug Development Immunity 
pharmaphorum
MARCH 24, 2022
GlaxoSmithKline has thrown its financial and drug development weight behind LifeMine Therapeutics, a US startup that aims to find new therapeutics from fungi – widely regarded as an underexplored resource of biologically-active compounds.
European Pharmaceutical Review
DECEMBER 16, 2022
According to a report by Future Market Insights (FMI), the global Alzheimer’s therapeutics market is expected to grow at a compound annual growth rate (CAGR) of 9.3 FMI stated drug manufacturers have been unable to validate the significant clinical benefits of treatment for numerous new compounds due to strict regulations.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
DECEMBER 5, 2022
Despite this, the medical use of cannabinoid drugs is heavily restricted, including being banned in 137 countries, according to the United Nations. Cannabinoid-based drugs are derived from compounds found in the cannabis plant. Cannabinoid receptors fall into two categories: CB1 and CB2 receptors.
pharmaphorum
AUGUST 27, 2020
Regulatory pressures, lengthy drug development times, and the fact that drug prices have become politicised have raised risks and cut revenue projections, leading to the biotech sector falling out of fashion. The first is that the development of vaccines is utilising cutting edge technologies.
Express Pharma
APRIL 4, 2024
Advantages of lipids and essential factors in selection Lipid-based formulations play a pivotal role in drug discovery and delivery, enhancing bioavailability by controlling therapeutic compounds’ solubility, permeability, absorption, distribution, and metabolism.
Pharmaceutical Technology
AUGUST 12, 2022
Adoptive cell therapy (ACT) is a form of cancer treatment that involves the transfer of immune cells into a patient to help fight the disease, by eliminating cancer cells. By 2028, the market is expected to reach $25 billion, with a compound annual growth rate (CAGR) of 46.6%. billion in 2021 and is forecast to reach $2.4
pharmaphorum
FEBRUARY 19, 2021
Rigel’s clinical-stage R552 is the main asset in the deal – which also includes $835 million in development, regulatory, and commercial milestones – but Lilly has also taken rights to preclinical-stage follow-ups that can cross into the brain and may have potential in central nervous system disorders.
Expert insights. Personalized for you.
105 
Let's personalize your content